Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.73 +0.00 (+0.05%)
As of: Aug 21, 2026 · 9:53 AM EDT

Drugs Made In America Acquisition (DMAA) Notes Payables (2024 - 2025)

Drugs Made In America Acquisition's (DMAA) quarterly Notes Payables came in at $60898.0 in Q1 2025, down 90.81% on a QoQ basis from $662324.0 in Q4 2024.

Drugs Made In America Acquisition (DMAA) Notes Payables (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 2 years of Notes Payables data on file, last reported at $60898.0 in Q1 2025.

  • Quarterly Notes Payables changed N/A year-over-year to $60898.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $60898.0 (changed N/A YoY) and the FY2024 annual result came in at $662324.0, changed N/A from the prior year.
  • Notes Payables declined to $60898.0 in Q1 2025, from $662324.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $662324.0 in Q4 2024 to a low of $60898.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn -
3 Drugs Made In America Acquisition 506.00 Mn 506.00 Mn -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn -
6 Aldel Financial 397.49 Mn 397.49 Mn -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn -
8 Gores Holdings X 385.06 Mn 384.87 Mn -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn -
10 Drugs Made In America Acquisition 215.62 Mn 215.62 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2025 60,898.00
Dec 31, 2024 662,324.00